Biontech to acquire biotheus to boost oncology strategy

Mainz, germany, november 13, 2024 (globe newswire) -- biontech se (nasdaq: bntx, “biontech”) and biotheus (“biotheus”) today announced the signing of a definitive agreement for the acquisition of biotheus, a clinical-stage biotechnology company dedicated to the discovery and development of novel antibodies to address unmet medical needs of patients with oncological or inflammatory diseases.

BNTX Ratings Summary

BNTX Quant Ranking